Arcadia Biosciences
RKDA
20 hedge funds and large institutions have $15.9M invested in Arcadia Biosciences in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 13 closing their positions.
0.83% less ownership
Funds ownership: 14.61% → 13.79% (-0.83%)
20% less funds holding
Funds holding: 25 → 20 (-5)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
63% less capital inflows, than outflows
Capital inflows: $582K | Capital outflows: $1.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
L. Roy Papp & Associates
Phoenix,
Arizona
|
+$239K |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
+$157K |
| 3 |
Paloma Partners
Greenwich,
Connecticut
|
+$65.3K |
| 4 |
Credit Suisse
Zurich,
Switzerland
|
+$40.2K |
| 5 |
Millennium Management
New York
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS O'Connor
Chicago,
Illinois
|
-$545K |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
-$363K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$194K |
| 4 |
BlackRock Institutional Trust
San Francisco,
California
|
-$141K |
| 5 |
BlackRock Investment Management
Wilmington,
Delaware
|
-$51.9K |
RKDA Hedge Fund Activity: Q2 2016 in Review
20 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q2 2016, worth a combined $15.9M — down 12% from $18M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of RKDA and 8 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was L. Roy Papp & Associates, adding an estimated $239K. The largest seller was UBS O'Connor, exiting entirely with an estimated $545K sold.
- 20 institutional investors held Arcadia Biosciences (RKDA) as of Q2 2016, down from 25 in Q1 2016.
- Funds reported $15.9M of Arcadia Biosciences stock for Q2 2016, down 12% quarter-over-quarter.
- 8 funds opened new Arcadia Biosciences positions in Q2 2016 and 13 closed out, a net change of -5 holders.
- The largest Arcadia Biosciences buyer in Q2 2016 was L. Roy Papp & Associates, an estimated $239K added.
- The largest Arcadia Biosciences seller in Q2 2016 was UBS O'Connor, an estimated $545K sold.
Based on aggregated 13F filings for Q2 2016.